Clinical Trial Results:
AC-055-310/ORCHESTRA: A pulmOnary aRterial hypertension study with maCitentan to validate tHE PAH-SYMPACT® in FRAnce, Italy, and Spain
A multi-center, open-label, single-arm, Phase 3b study of macitentan in patients with pulmonary arterial hypertension to psychometrically validate the French, Italian, and Spanish versions of the PAH-SYMPACT®
Summary
|
|
EudraCT number |
2013-003462-14 |
Trial protocol |
IT ES |
Global end of trial date |
09 Sep 2015
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
07 May 2017
|
First version publication date |
07 May 2017
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
AC-055-310
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT02081690 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
ACTELION Pharmaceuticals Ltd.
|
||
Sponsor organisation address |
Gewerbestrasse 16, Allschwil, Switzerland, 4123
|
||
Public contact |
Laurie Bertrand, ACTELION Pharmaceuticals Ltd., 41 61 565 83 36,
|
||
Scientific contact |
Laurie Bertrand, ACTELION Pharmaceuticals Ltd., 41 61 565 83 36,
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
09 Sep 2016
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
09 Sep 2015
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
09 Sep 2015
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To evaluate the psychometric characteristics of reliability and construct validity of the French, Italian, and Spanish versions of the PAH-SYMPACT®
|
||
Protection of trial subjects |
The protocol and any material provided to the patient (such as a patient information sheet or description of the study used to obtain informed consent) were reviewed and approved by the appropriate Independent Ethics Committee (IEC) or Institutional Review Board (IRB), i.e., a review panel that was responsible for ensuring the protection of the rights, safety and well-being of the study subjects.
Actelion and investigators ensured that the study was conducted in full compliance with the principles of the ʽDeclaration of Helsinkiʼ and with the laws and regulations of the country in which the research was conducted. GCP training was provided to investigators and investigational site staff. Both Actelion and the investigator had the right to terminate the study at any time, and in such a case, were responsible for protecting the subjects’ interests.
Written informed consent was obtained from each individual participating in the study prior to any study procedure and after adequate explanation of the aims, methods, objectives, and potential hazards of the study. It was made clear to each patient that he or she was completely free to refuse to enter the study, or to withdraw from it at any time for any reason.
|
||
Background therapy |
Concomitant treatment with oral diuretics was allowed if patients had been on a stable dose for at least 1 week prior to Baseline period and up to the Treatment Initiation visit. The following treatments for PAH were allowed if patients had been on a stable dose for at least 3 months before the Treatment Initiation visit: • Oral PDE-5 inhibitors; • Inhaled prostacyclin analogs; • Calcium channel blockers. Forbidden concomitant therapy included: • ERAs, i.v. or s.c. prostanoids, and soluble guanylate cyclase stimulator unless initiated for clinical worsening of PAH; • Strong CYP3A4 inducers; • Any investigational drug. | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
27 Feb 2014
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
France: 42
|
||
Country: Number of subjects enrolled |
Italy: 17
|
||
Country: Number of subjects enrolled |
Spain: 29
|
||
Worldwide total number of subjects |
88
|
||
EEA total number of subjects |
88
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
59
|
||
From 65 to 84 years |
29
|
||
85 years and over |
0
|
|
|||||||||||||||
Recruitment
|
|||||||||||||||
Recruitment details |
The study was conducted in 3 countries (France, Italy, and Spain), with patients enrolled in 37 centers. | ||||||||||||||
Pre-assignment
|
|||||||||||||||
Screening details |
The screening period lasted from Day −28 to Day −15 and included the Screening Visit (Visit 1). | ||||||||||||||
Period 1
|
|||||||||||||||
Period 1 title |
Baseline period
|
||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||
Allocation method |
Not applicable
|
||||||||||||||
Blinding used |
Not blinded | ||||||||||||||
Arms
|
|||||||||||||||
Arm title
|
Baseline period | ||||||||||||||
Arm description |
Baseline period | ||||||||||||||
Arm type |
No IMP | ||||||||||||||
Investigational medicinal product name |
No IMP
|
||||||||||||||
Investigational medicinal product code |
|||||||||||||||
Other name |
|||||||||||||||
Pharmaceutical forms |
Anticoagulant and preservative solution for blood
|
||||||||||||||
Routes of administration |
Other use
|
||||||||||||||
Dosage and administration details |
No IMP
|
||||||||||||||
|
|||||||||||||||
Period 2
|
|||||||||||||||
Period 2 title |
Macitentan treatment period
|
||||||||||||||
Is this the baseline period? |
No | ||||||||||||||
Allocation method |
Not applicable
|
||||||||||||||
Blinding used |
Not blinded | ||||||||||||||
Arms
|
|||||||||||||||
Arm title
|
Macitentan | ||||||||||||||
Arm description |
Macitentan 10 mg o.d. | ||||||||||||||
Arm type |
Experimental | ||||||||||||||
Investigational medicinal product name |
Macitentan
|
||||||||||||||
Investigational medicinal product code |
|||||||||||||||
Other name |
|||||||||||||||
Pharmaceutical forms |
Film-coated tablet
|
||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||
Dosage and administration details |
Macitentan 10 mg o.d. for 16 weeks
|
||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Baseline period
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Baseline period | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis sets
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
Full Analysis Set
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Full analysis | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
The Full Analysis Set (FAS) included all enrolled patients.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
Safety Set
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Safety analysis | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
The Safety Set (SS) included all patients who received at least one dose of study treatment, based on the actual treatment received
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
Validation Analysis Set
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Per protocol | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
Validation Analysis Set (VAS) comprised data from all patients included in the FAS who had no protocol deviation(s) that could affect the analysis.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
Per-protocol Set
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Per protocol | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
The Per-protocol Set (PPS) comprised data from all patients included in the FAS who did not have any of the following protocol deviations:
• Patients who did not receive study treatment
• Patients who violated selected inclusion/exclusion criteria
• Patients who received a prohibited concomitant PAH medication
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Baseline period
|
||
Reporting group description |
Baseline period | ||
Reporting group title |
Macitentan
|
||
Reporting group description |
Macitentan 10 mg o.d. | ||
Subject analysis set title |
Full Analysis Set
|
||
Subject analysis set type |
Full analysis | ||
Subject analysis set description |
The Full Analysis Set (FAS) included all enrolled patients.
|
||
Subject analysis set title |
Safety Set
|
||
Subject analysis set type |
Safety analysis | ||
Subject analysis set description |
The Safety Set (SS) included all patients who received at least one dose of study treatment, based on the actual treatment received
|
||
Subject analysis set title |
Validation Analysis Set
|
||
Subject analysis set type |
Per protocol | ||
Subject analysis set description |
Validation Analysis Set (VAS) comprised data from all patients included in the FAS who had no protocol deviation(s) that could affect the analysis.
|
||
Subject analysis set title |
Per-protocol Set
|
||
Subject analysis set type |
Per protocol | ||
Subject analysis set description |
The Per-protocol Set (PPS) comprised data from all patients included in the FAS who did not have any of the following protocol deviations:
• Patients who did not receive study treatment
• Patients who violated selected inclusion/exclusion criteria
• Patients who received a prohibited concomitant PAH medication
|
|
|||||||||||||||||||||||||||||||
End point title |
Psychometric validation of the French, Italian and Spanish versions of the PAH-SYMPACT™ patient-reported outcome tool [1] | ||||||||||||||||||||||||||||||
End point description |
Evaluation of the psychometric characteristics of reliability and construct validity of the PAH-SYMPACT, and the ability of the PAH-SYMPACT to detect change.
|
||||||||||||||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||||||||||||||
End point timeframe |
From Screening Visit (Visit 1) to End of Treatment (EOT) Visit (Visit 4, Week 16)
|
||||||||||||||||||||||||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Not applicable due to specific study design |
|||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Change in the PAH-SYMPACT symptom and impact scores assessed by Clinician Global Impression of Change (CGI-C) | ||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
Change in the PAH-SYMPACT symptom and impact scores assessed by the PAH-SYMPACT questionnaire - Clinician Global Impression of Change (CGI-C)
|
||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
From Baseline Visit (Visit 2, Day 1) to Week 16
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Statistical analysis title |
Statistical analysis 1 | ||||||||||||||||||||||||||||||||||||||||||||||||
Statistical analysis description |
Not applicable
|
||||||||||||||||||||||||||||||||||||||||||||||||
Comparison groups |
Macitentan v Per-protocol Set
|
||||||||||||||||||||||||||||||||||||||||||||||||
Number of subjects included in analysis |
174
|
||||||||||||||||||||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||||||||||||||||||||
Analysis type |
other [2] | ||||||||||||||||||||||||||||||||||||||||||||||||
P-value |
= 0 [3] | ||||||||||||||||||||||||||||||||||||||||||||||||
Method |
Not applicable | ||||||||||||||||||||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||||||||||||||||||||
Notes [2] - Not applicable [3] - Not applicable |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Change in the PAH-SYMPACT symptom and impact scores assessed by Patient Global Assessment of Disease Severity (PGA-S) [4] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
Mean change in the PAH-SYMPACT symptom and impact scores assessed by the PAH-SYMPACT questionnaire - Patient Global Assessment of Disease Severity (PGA-S)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
From Baseline Visit (Visit 2, Day 1) to Week 16
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes [4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Not applicable due to specific study design |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
From study treatment initiation up to 30 days after study treatment discontinuation
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
18
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Macitentan
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Macitentan | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |